
Arcellx (NASDAQ:ACLX) is advancing into pivotal testing (by year-end 2022) of its B-cell maturation antigen (BCMA) directed combination antiretroviral therapy (CART), known as ddBCMA, for relapsed refractory multiple myeloma, according to BofA Securities.
The Arcellx Analyst: Jason Gerberry initiated coverage of Arcellx with a Buy rating and a price target of $24.